Analysis of pharmacokinetics of Gd-DTPA for dynamic contrast-enhanced magnetic resonance imaging.
The pharmacokinetics (PK) of the contrast agent Gd-DTPA administered intravenously (i.v.) for contrast-enhanced MR imaging (DCE-MRI) is an important factor for quantitative data acquisition. We studied the effect of various initial bolus doses on the PK of Gd-DTPA and analyzed population PK of a lower dose for intra-subject variations in DCE-MRI. First, fifteen subjects (23-85years, M/F) were randomly divided into four groups for DCE-MRI with different Gd-DTPA dose: group-I, 0.1mmol/kg, n=4; group-II, 0.05mmol/kg, n=4; group-III, 0.025mmol/kg, n=4; and group-IV, 0.0125mmol/kg, n=3. Sequential fast T1 mapping sequence, after a bolus i.v. Gd-DTPA administered, and a linear T1-[Gd-DTPA] relationship were used to estimate the PK of Gd-DTPA. Secondly, MR-acquired PKs of Gd-DTPA from 58 subjects (28-80years, M/F) were collected retrospectively, from an ongoing study of the brain using DCE-MRI with Gd-DTPA at 0.025mmol/kg, to statistically analyze population PK of Gd-DTPA. We found that the PK of Gd-DTPA (i.v. 0.025mmol/kg) had a half-life of 37.3±6.6min, and was a better fit into a linear T1-[Gd-DTPA] relationship than higher doses (up to 0.1mmol/kg). The area under the curve (AUC) for 0.025mmol/kg was 3.37±0.46, which was a quarter of AUC of 0.1mmol/kg. In population analysis, a dose of 0.025mmol/kg of Gd-DTPA provided less than 5% subject-dependent variation in the PK of Gd-DTPA. Administration of 0.025mmol/kg Gd-DTPA enabled us to estimate [Gd-DTPA] from T1 by using a linear relationship that has a lower estimation error compared to a non-linear relationship. DCE-MRI with a quarter dose of Gd-DTPA is more sensitive to detect changes in [Gd-DTPA].
Pharmaceutical Department, University of South Florida, Tampa, FL, 33647, United States; Department of Physiology, University of New, Mexico, Health Sciences Center Albuquerque, NM, 87131. Electronic address: taheris@health.usf.edu.
Saeid
S
Taheri
Institute of Neuroscience and Medicine-4, Research Centre Jülich, 52425, Jülich, Germany; Department of Neurology, Faculty of Medicine, RWTH Aachen University, Aachen, Germany; Jülich Aachen Research Alliance (JARA)-Translational Brain Medicine, Aachen and Jülich, Germany.
N Jon
NJ
Shah
Department of Physiology, University of New, Mexico, Health Sciences Center Albuquerque, NM, 87131; Department of Neurology, Neuroscience, and Cell Biology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, United States.
Gary A
GA
Rosenberg
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019540:Area Under Curve; D001921:Brain / Q000000981:diagnostic imaging*; D003287:Contrast Media / Q000378:metabolism / Q000493:pharmacokinetics*; D005260:Female; D019786:Gadolinium DTPA / Q000097:blood / Q000493:pharmacokinetics*; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D019047:Phantoms, Imaging; D015203:Reproducibility of Results; D012189:Retrospective Studies
D003287:Contrast Media; D019786:Gadolinium DTPA
Contrast media; Gd-DTPA; MRI; Magnetic resonance imaging; Pharmacokinetics